Loading
Latest filing published 06 May 2022 for LianBio, €1.6M.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Filings by Debra Yu span 2 companies, the busiest being Ascentage Pharma Group International and LianBio. Over a trading history stretching from 4 May 2022 to 26 November 2025, the count stands at 3 filings.
The open-market record is one-sided, with 2 purchases and not one sale. No amount is published for 2 filings, which the totals therefore leave out. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 1 option exercise. In 2025 alone, the filings show 2 purchases and no sales.
Most recently, on 30 December 2025, the filings show an open-market purchase in Ascentage Pharma Group International. Filings reach the SEC (Form 4) feed a median of 34 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 of 1 declaration